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Mutations in LAMA5 disrupts a skeletal noncanonical focal adhesion pathway and 
produces a distinct bent bone dysplasia
INTRODUCTION
In addition to its structural role in skeletogenesis, the extracellular matrix
(ECM), particularly basement membrane proteins, facilitates communication
with intracellular signaling pathways and cell to cell interactions to control
differentiation, proliferation, migration and survival. Alterations in
extracellular proteins cause a number of skeletal disorders and one
attributed mechanism results from the deleterious effects of mutated
proteins on ECM structure. Yet, the consequences of abnormal ECM on
cellular communication remains less well understood. Herein, we describe
an unclassified form of bent bone dysplasia caused by recessively inherited
mutations in LAMA5, the gene encoding the alpha-5 laminin basement
membrane protein. This finding uncovered a mechanism of disease driven
by ECM-cell interactions between alpha-5-containing laminins, and integrin-
mediated focal adhesion signaling, particularly in cartilage. Loss of LAMA5
altered b1 integrin signaling through the non-canonical kinase PYK2 and the
skeletal enriched SRC kinase FYN. Loss of LAMA5 negatively impacted the
actin cytoskeleton, vinculin localization, and WNT signaling, tying focal
adhesion molecules to key skeletal signaling molecules. This newly described
mechanism reveals that a LAMA5-b1 Integrin-PYK2-FYN focal adhesion
complex regulates skeletogenesis and, when dysregulated, produces a
distinct skeletal disorder. .
CONCLUSIONS
LAMA5 has an important role in skeletogenesis and its mutations cause a distinctive skeletal dysplasia
These results define a new pathway for skeletogenesis involving LAMA5-Integrins-PYK2 and FYN
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Radiographic findings in R03-206G. Full term fetus with enlarged skull (A),
micrognathia (B), presence of scapula and elbow dislocations (C), slight
bowing of the humerus, radius and ulna (C, D), severely bent femurs with
cortical abnormalities (E), platyspondyly with coronal clefts (F), aplastic
acetabular roofs (G) ulnar deviation and contractures in the hands (H) and
bilateral equinovarus (I, J).
Compound heterozygous missense mutations in LAMA5 destabilize the α5 laminin subunit.
(A) Three affected siblings (R03-206A, B, G) showed the bent bone dysplasia phenotype. (B)
Each parent (R03-206E, D) carried one of the mutations. (C) The mutations localized close to
EGF domains of the LAMA5 protein. (D, E) Affected patient derived chondrocytes and
fibroblasts showed reduced levels of LAMA5, *p<0.05, **p<0.01. (F) Similar reduction was
observed in cartilage derived from the affected individual R03-206G, ***p<0.001.
LAMA5 localization in the skeleton. (A) LAMA5 staining in a fetal 18 week musculoskeletal
tissues. LAMA5 localized around blood vessels in cartilage, ligaments and bone (C-E) and
independently of blood vessels in articular cartilage, periosteum and growth plate (B, G, F).
Bars represent 50μm.
Deficient LAMA5 disrupts the focal adhesion pathway. (A) Chondrocytes from R03-206G showed
decreased levels of integrin β1, total PYK2, pPYK2, p-P130CAS, and pPaxillin. (B) Similar changes were
observed in HeLa LAMA5Hyp/Hyp. (C) Quantitative PCR statistical analysis of the expression of gene-edited
HeLa cells with the LAMA5Hyp/Hyp allele. (D-N) Quantification of protein levels in chondrocytes and Hela cells
from A and B, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
LAMA5 mutant chondrocytes and LAMA5Hyp/HypHela cells dysregulate SRC kinase expression levels. (A)
Chondrocytes from R03-206G showed decreased levels of p-SRC family. (B) A similar decrease in p-SRC
family, as well as in FYN, was observed in HeLa LAMA5Hyp/Hyp cells. (C) Quantitation of the decreased FYN
levels in LAMA5Hyp/Hyp HeLa cells shown in B. (D-J) PYK2 localizes similarly to LAMA5 around blood vessels
in cartilage, ligaments and bone as well as articular cartilage growth plate and
periosteum/perichondrium in human skeletal tissue. (K-Q) FYN shows a very similar pattern with the
exception of proliferative and hypertrophic growth plate chondrocytes, where it was not seen. Bars
represent 50um.
Effects on cell adhesion due to loss of LAMA5
(A) Chondrocytes from R03-206G and (C) LAMA5Hyp/HypHeLa cells showed no change in total VCL levels compared to controls. (B, D)
Quantitation of the data shown in A, B. (E-F) Focal adhesions were visualized by immunostaining with anti-VCL (green) and actin marker
phalloidin (red). Nuclei were stained with DAPI (blue). Bars represent 20μm. (G) LAMA5Hyp/HypHeLa cells have deficient migration. The
LAMA5Hyp/Hyp cells healed more slowly than the control cells at 24 hours (92.8±1.6% vs. 82.8±2.2% (p=0.0013). The orange lines indicate
borders of the cell-less regions. Scale bars, 100 µm. (H) Equal numbers of Hela cells were plated and the cell numbers were calculated
on three consecutive days and plotted as values relative to the first day of measurement (t0). No differences in proliferation between
control and LAMA5Hyp/Hyp cells were found.
Defective LAMA5 alters WNT signaling pathway. (A) TCF/LEF promoter showed a decreased activity in R03-206G patient
chondrocytes when induced with 100 ng/ml WNT3A for 30 minutes. (B) Similar changes were observed in LAMA5Hyp/Hyp cells
after application of 100 ng/ml WNT3A. (C-H) Defective LAMA5 cells showed reduced LRP6 phosphorylation after a 30-
minute incubation with 50ng/ml WTN3A. *p<0.05, **p<0.01, ****p<0.0001.
